German
€0.00*
Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

  • Question of the Week

Passive containers are cost-effective and easy to use, relying on insulation and coolants like ice packs, but they only maintain stable temperatures for limited times, making them less suitable for long or sensitive shipments.

[GMP:KnowHow Pharma Logistics (GDP), Chapter 9.3]

Would you like to discover more?

GMP:KnowHow Pharma Logistics (GDP) is your perfect tool for GDP-compliant storage and transportation.

The free demo access is non-binding and ends automatically after 7 days. 

Test it now for free

You may also be interested in the following articles:

News: Artificial Intelligence
News

Annex 22: Results of the EMA Workshop

On 30 June, the EMA’s Annex 22 Working Group discussed the future scope of the annex with AI experts and representatives of the pharmaceutical industry (as previously reported).
Read more
News: Artificial Intelligence
News

EMA Workshop Regarding Annex 22 "Artifical Intelligence"

The current draft of Annex 22, "Artificial Intelligence", proposes excluding generative AI and large language models (LLMs), as well as probabilistic, dynamic and adaptive AI models, from critical GMP applications. Numerous comments submitted during the public consultation challenged this approach. Instead, the aim should be to support innovation and encourage investment by the pharmaceutical industry.
Read more
Question of the Week | GMP-Verlag
Question of the Week

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements
LOGFILE Feature

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines
News

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates
News

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
Previous
Next
This website uses cookies to ensure the best experience possible. More information...